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Lenalidomide is an oral immunomodulatory drug used in multiple myeloma and myelodysplastic syndrome and most recently it
has shown to be effective in the treatment of various lymphoproliferative disorders such as chronic lymphocytic leukemia (CLL) and
non-Hodgkin lymphoma. The mechanism of action of lenalidomide varies depending on the pathology, and in the case of CLL, it
appears to primarily act by restoring the damaged mechanisms of tumour immunosurveillance.This review discusses the potential
mechanism of action and efficacy of lenalidomide, alone or in combination, in treatment of CLL and its toxic effects such as tumor
lysis syndrome (TLS) and tumor flare reaction (TFR), that make its management different from other hematologic malignancies.
1. Introduction on Chronic
Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is the most common
form of leukemia in adults in Western countries. In our
population, the crude rate is 8.99 per 100.000 populations
per year and the age-adjusted rate is 3.47 per 100.000
populations per year. Overall survival at 5 and 10 years is
ranged between 87% and 73% for low-risk patients and 29%
and 16% for high risk [1]. In addition, the clinical course
of the disease is very heterogeneous; some patients require
treatment after a long time, while others rapidly progress with
a few months of survival. Patients who relapse frequently
show poor prognostic genetic characteristics, such as del
(17p) or TP53, that confer them resistance to cytostatic drugs
such as fludarabine [2, 3].
Microenvironment and immune system play a key role
in the pathogenesis of CLL. Tissuemicroenvironment signals
promote leukemic cell proliferation, survival, and resistance
to chemotherapy. For instance, IL-4 secreted by T cells
induces the overexpression of antiapoptotic proteins, such
as bcl-2, in leukemic cells [4]. Additionally, one of the
key features of CLL is the development of a progressive
immunodeficiency which is associated with an increased
incidence of infections and secondary malignancies. In
addition, numerous qualitative and quantitative alterations
affecting all components of the immune system including T
cells, NK cells, dendritic cells, and cytokine production have
been described [5, 6].
A better understanding of the biology of the disease
and tumor microenvironment has opened new ways for the
development of immunotherapy-based treatments. The use
of immunotherapy is of particular interest in this disease
because the alteration of the immune system is further
aggravated by the use of chemotherapeutic agents such as
fludarabine and cyclophosphamide with rituximab (FCR)
which are the current standards in frontline therapy. It is
interesting to highlight that in a high percentage of patients
the cause of death is related to immunodeficiency. Presum-
ably, the activation of the immune system may ameliorate
the immunodeficiency and repair the antileukemic immunity
producing durable clinical responses.
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2. Mechanism of Action of Lenalidomide
Lenalidomide is an antineoplastic agent that exerts its anti-
tumor action through various mechanisms such as activation
of the immune system, inhibition of angiogenesis, and direct
antineoplastic effects. The mechanisms of action may vary
according to the disease, but there is growing evidence
indicating that lenalidomide does not have a direct cytotoxic
effect onCLL cells, but instead, it acts primarily by promoting
and restoring the function of the immune system. Contrarily,
changes in the serum concentrations of VEGF or in the
density of the microvasculature in the bone of CLL patients
who responded to lenalidomide treatment have not been
found [7].
Functional immune reconstitution seems essential for
the antileukemic activity of lenalidomide in CLL [8]. When
lenalidomide is administered in cycles of 21 days, there is
a rapid increase of the number of lymphocytes in the off-
treatment week [9]. The stimulation of the immune system
seems to be pleiotropic affecting different cells and functions.
Lenalidomide causes an overexpression of costimulatory
molecules in leukemic lymphocytes inducing an “activation
phenotype” that restores the humoral immunity and the
production of immunoglobulins [10]. It also improves the
function of T cells and the ability of leukemic cells to form
synapses with T lymphocytes [11]. There is also an increase
of the number and the cytotoxic capacity of NK cells and a
reduction of the number and suppressor activity of Treg cells
[12].
2.1. Effects of Lenalidomide on Leukemic Cells. In contrast to
normal B cells, leukemic cells are poor antigen presenting
cells.This is due to the fact that leukemic cells have a reduced
expression of costimulatory molecules such as CD80 and
CD86 and they have a defect in the formation of immuno-
logical synapse with T cells. After lenalidomide treatment,
there is an overexpression of costimulatory molecules and
activation markers in leukemic B cells such as CD40, CD80,
CD86, CD54, CD95 (Fas), DR5 andHLA-DR [9, 13]. Immune
activation in CLL and the overexpression of costimulatory
molecules may not only be responsible for the antineoplastic
activity of lenalidomide, but also for the tumor flare syn-
drome (TFR) that affects someCLL-treated patients [7]. It has
also been observed that lenalidomide restores the humoral
immunity, since it induces the expression of CD154 (also
known as CD40L) on T cells, which not only increases the
sensitivity of leukemic cells to apoptosis, but it also activates
normal B cells favoring the production of antibodies. Among
them, there are some anti-tumor antibodies such as anti-
ROR1 [14].
2.2. Lenalidomide Activates Other Lymphocyte Subpopula-
tions. In CLL patients receiving lenalidomide as a first-line
monotherapy, quantitative changes in lymphocyte subpopu-
lations were observed after 21 days of treatment. There was a
decrease in the number of CD19/CD5+ leukemic cells and an
increase in the percentage ofCD4T cells, CD8T cells, andNK
cells [13]. It is worth mentioning that lenalidomide activates
CD8 T cells and NK cells that play a key role in the tumor
surveillance.
Using lenalidomide monotherapy as first line, it was
reported that the absolute number of lymphocytes decreased
(mainly at the expense of leukemic lymphocytes) after three
cycles of treatment.There was an increase of IFN-𝛾 produced
by CD8 T cells and Treg compared with their levels before the
treatment [15]. The early increase of IFN-𝛾 produced by CD8
T cells indicates that the cytotoxicity mediated by these cells
may be involved in the mechanism of action of lenalidomide
[15]. Nevertheless, the levels of T cells returned to normal
values after 14 months of treatment. Similarly, there was an
increase in the levels of CD4 T cells that produce IL-2, IFN-
𝛾, and TNF-𝛼 with respect to the baseline values and normal
individuals. The elevation of CD4 T cells persisted for three
months, returning to normal values at fourteen months [15].
Many of the immunomodulatory effects of lenalidomide
occur via secretion of cytokines. In the study Ferrajoli et al.,
patients who respond to lenalidomide showed significant
increases in the IL-2R, IL-6, and IL-10 levels [7] that may
have a direct effect on immune cells. Likewise, Davies et al.
demonstrated that lenalidomide is able (in vitro) to stimulate
mononuclear cells in an IL-2-dependent manner, so they are
able to kill myeloma cells [16]. This effect was abolished by
the depletion of CD56+ cells suggesting that NK or NKT
cells mediate this effect. Moreover, an increase of CD56+
cells in responding patients was observed, suggesting that
the lenalidomide therapeutic activity may be mediated by the
increase of the number and function of NK cells [16].
In vitro, lenalidomide stimulates NK cell activity at least
through the production of IL-2 by T cells increasing the
antibody-dependent cellular cytotoxicity (ADCC) mediated
by these cells [17]. In vivo, an increase of NK cells in
lenalidomide-treated patients has been observed; however,
these cells showed a decrease in its activation level, having
a concomitant enhancement of the cytotoxicity of CD8 T
lymphocytes [18]. In addition to NK cells, lenalidomide also
induces NKT cell expansion and stimulates its antitumor
activity [19].
Overall, lenalidomide has a pleiotropic effect promoting
several elements of the antitumor immune response.The role
of each mechanism of action on the therapeutic activity of
lenalidomide remains to be elucidated.
2.3. Mechanism of Action of Lenalidomide Associated with
Rituximab. We have observed that in CLL, lenalidomide
mainly acts promoting the proliferation and activation of
NK cells ex vivo. However, the capacity of lenalidomide to
promote the antileukemic activity of NK cells is limited.
This is due to the fact that tumor cells are detected by NK
cells through changes in their receptors ligand expression.
However, leukemic cells of CLL patients express low levels
of ligands of NK cell activating receptors, probably due to
immune evasion mechanisms, being highly resistant to NK
cell-mediated activation. To increase the cytotoxic activity
against leukemia cells, it is necessary to favor the recognition
of leukemia cells byNK cells. According to this idea, lenalido-
mide is an attractive agent for combination with rituximab.
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Rituximab allows the elimination of CD20+ leukemia cells
through the receptor for IgG called CD16 from NK cells, by
antibody-dependent cytotoxicity or ADCC. In vitro, it has
been reported that lenalidomide decreases the leukemic cells
CD20 expression, antagonizing the effect of rituximab [20],
but this has not been confirmed [13]. In addition, we have
found that the lenalidomide effect on CD20 expression on
leukemic cells is variable, but independently, lenalidomide
has a synergistic effect with rituximab. Following this idea,
lenalidomide is an attractive agent to combine with other
agents which favour the activity of NK cells.
3. Lenalidomide Efficacy
3.1. Use of Lenalidomide in Chronic Lymphocytic Leukemia.
Lenalidomide, a derivative of thalidomide, is an immunomo-
dulatory drug with significant activity in CLL.The efficacy of
lenalidomide in monotherapy is comparable to other single
cytotoxic agents used in this disease. In recent years, several
phase II clinical trials have demonstrated the effectiveness
of lenalidomide in CLL patients who relapsed or were
refractory to previous treatments that included fludarabine;
better results have been obtained when used as a first-line
treatment [7, 9, 21].
The first clinical trial demonstrating the clinical activity
of lenalidomide in CLL is a randomized phase II study
analysing 45 patients with relapsed or refractory disease [21].
In this study, lenalidomide was initiated at 25mg daily in
28 day cycles. After two cases of TLS, the starting dose was
reduced to 5mg, with escalations to a maximum of 25mg.
In heavily pretreated patients with CLL (51% fludarabine
refractory), ORR was 47% and complete remission (CR) was
9% [21]. In another phase II trial, in 44 patients using a
more cautious dosing schedule (starting at 10mg daily and
increasing 5mg every 28 days to a maximum of 25mg),
overall response decreased to 32% (CR 7%), but side effects
were significantly reduced [7]. In a phase I study using a low
starting dose of 2.5mg, and escalating 5mg each 28 days to 10,
15, and 20mg, one-third of patients could not escalate beyond
2.5mg, although those who reached 20mg did not suffer any
dose-limiting toxicities [22]. This schedule with a low initial
dose and further escalation has been adopted in subsequent
clinical trials. In another study with a pulse dosing schedule
of 21 days with 21 days off, global responses decreased to 16%,
but toxicity was similar [10].
Of considerable interest is its usefulness in patients with
adverse features. It has been reported that in patients with
high-risk cytogenetic features, the ORR was 31–38%; in
cases with nonmutated IgH, it was 24%; and in patients
with fludarabine-refractory disease, it was 25–30% [7, 23].
Likewise, lenalidomide treatment, alone or in combination,
became an effective alternative in these patients. In CLL
patients with del(17p) pretreated with different regimens, 8
who were treated with lenalidomide obtained an ORR of 38%
(CR 13%) and an overall survival (OS) of 11 months, which
are better results than obtained with other combinations
currently used in these patients [24]. The ORR improved up
to 72%with lenalidomidemonotherapy as first-line treatment
with a prolonged followup of 47 months [25].
The overall response rate (ORR) of lenalidomide mono-
therapy as first-line therapy was 65% in elderly patients
[26]. This study demonstrates that longer therapy and higher
doses of lenalidomide are more effective to obtain responses.
Nevertheless, the ORIGIN trial (NCT00910910), which has
recently evaluated the use of lenalidomide treatment as an
initial therapy for CLL patients of 65 or older, showed higher
rates of death in patients treated with lenalidomide compared
with those treated with chlorambucil (hazard ratio (HR) of
1.92). FDA has halted this study after determining that this
treatment was unlikely to achieve an improved progression-
free survival in these older patients (primary objective).
Table 1 shows the response, survival rates, and adverse
effects of several studies using different regimens of lenalido-
mide monotherapy as first-line or salvage treatment in
relapsed CLL patients. Most of these trials begin with a low
dose and then try to escalate to the target dose [22, 26–28].
3.2. Lenalidomide with Rituximab in Induction. The efficacy
of lenalidomide may be increased with the addition of other
agents such as rituximab. In several phase II clinical trials,
it has been demonstrated that the addition of rituximab
improved the response rates without increasing the toxicity.
In a high percentage of patients, the number of leukemic cells
declines within 8 days after the start of the treatment.
Badoux et al. reported that with this combination,
relapsed or refractory CLL patients achieved an ORR of 66%
(including 12% CR) and an estimated 36-month survival
of 71% [29]. In this study, lenalidomide was started with a
continuous dose of 10mg on day 9 of cycle 1 and rituximab
was added weekly (375mg/m2) during the first cycle and
then monthly (cycles 3 to 12). Although it cannot be directly
compared with the outcomes obtained in the monother-
apy studies, the encouraging ORR and sustained responses
observed suggest an increasing benefit with the addition
of rituximab, with less side effects and better tolerance.
Furthermore, rituximab administered before lenalidomide
could also act as a debulking agent reducing the rate and
severity of TFR.
In another phase II clinical trial using lenalidomide and
rituximab as the first-line therapy, overall responses were
higher than 90%. Moreover, this combination was safe with
an acceptable toxicity profile. Even seven patients with (17p)
deletion showed an ORR of 53% (CR 13%) [30]. Responses
with this combination were also obtained in 71% of patients
refractory to lenalidomide monotherapy [31].
The overall conclusion from these studies is that con-
tinuous treatment with this combination may probably
provide accumulative benefits [32]. Thus, combination of
lenalidomide with rituximab could offer an effective alter-
native for patients who relapsed after fludarabine-containing
chemoimmunotherapy. Nevertheless, further studies must be
implemented to obtain definite conclusions.
3.3. Other Combinations with Lenalidomide Induction. A
current phase II study using lenalidomide in combination
with ofatumumab demonstrates an acceptable toxicity profile
[33], and similar outcomes are shown in several phase I trials
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Table 1: Lenalidomide monotherapy trials in patients with CLL.
References Regimen No Response TLS TFR AE grade 3-4
Chanan Kh [21]
2007
Phase II
Relapsed or refractory
Lenalidomide 5mg per day
escalating up to 25mg per day 45
ORR 47%
RC 9%
OS: NR
TFS: NR
5% 58%
Neutropenia 70%
Thrombocytopenia 45%
Anemia 18%
Ferrajoli [7]
2008
Phase II
Relapsed or refractory
Lenalidomide 10mg per day
escalating up to 25mg/day
(5mg each 28 days)
Median 10mg
44
ORR 32%
RC: 7%
OS 73% at 14 months
TFS: NR
0 12%
Neutropenia 41%
Thrombocytopenia 13%
Anemia 3%
Chen [9, 25]
2011
Phase II
Untreated
Lenalidomide 2.5mg per week
escalating up to 10 mg or
25mg if no response
Median 18 cycles (2–33)
25
ORR 72%
OS 85.3%
TFS 68.8%
(estimated at 3 years)
0 88%
Neutropenia 76%
Thrombocytopenia 28%
Anemia 20%
Aue 2010 [10]
Phase II
Relapsed or refractory
Lenalidomide pulses:
10–20mg for 21 days followed
by 21 days of rest (4–8 cycles)
31
ORR 16%
RC 0
PFS responding 16 m
versus 6m
0 53%
Neutropenia 56%
Thrombocytopenia 30%
Anemia 15%
Infection
Badoux [26]
2011
Phase II
Elderly
Untreated
Lenalidomide 5mg monthly
increases to 25mg as tolerated
until disease progression or
unacceptable toxicity
60
(>65 years)
median 71 years
ORR 65%
RC 10%
OS 88%
TFS 60%
(estimated at 2 years)
0 52%
Neutropenia 83%
Thrombocytopenia 47%
Anemia <1%
Infection 10%
Lamanna [27]
Phase II
Treated and untreated
Continuous low dose 2.5mg
to 5mg is increased if
progression (up to 20mg)
21 7% 47% Neutropenia 52%Thrombocytopenia 24%
Wendter [28]
CLL-009
2011
Phase II
Relapsed or refractory
Initial doses of 5, 10, or 15mg
escalating up to 25mg (dose
finding)
60 ORR 37%RC 3.4% 3.4% 10%
Neutropenia 41,7%
Thrombocytopenia 25%
Anemia 8.3%
Wendter [22]
2012
CLL-001
Phase II
Treated
Continuous cycles of 28 days
increasing from 2.5mg to
25mg
52
ORR 12%
RC 0%
SD 58%
10%
Neutropenia 65%
Thrombocytopenia 33%
Anemia 10%
TLS: tumor lysis syndrome; TFR: tumor flare reaction; AE: adverse effects; NR: not reported; ORR: overall response; CR: complete remission; OS: overall
survival; SD: stable disease; TFS: treatment-free survival; m: months.
with other combinations (fludarabine, cyclophosphamide,
and lenalidomide [34]; fludarabine, rituximab, and lenalido-
mide [35]; the same combination followed of maintenance
with lenalidomide and rituximab [36] or in combinationwith
bendamustine [37] or flavopiridol [38] or alemtuzumab).
The tolerated dose of lenalidomide in these combinations
is generally low (5–10mg) and its efficacy is higher than in
lenalidomide monotherapy. In fludarebine-based combina-
tions even at the lowest dose level, dose-limiting toxicities
occurred in most patients.
The preliminary results obtained from a phase II study
with lenalidomide plus dexamethasone show a significant
activity in previously untreated CLL patients. Moreover, it
is generally well tolerated and reduces the incidence of side
effects, such as TFR, enabling the escalation to higher dose of
lenalidomide [39].
In another trial using lenalidomide consolidation after
6 cycles of pentostatin, cyclophosphamide, and rituximab
(PCR-L), an increase in the response quality was observed
and negative minimal residual disease (MRD) was shown
in some cases. The treatment-free survival (TLS) was higher
than a historical control (79% versus 66% at 30 months)
and the main toxicity observed was hematologic, but no
cases of TLS or TFR were described [40]. An improved
quality of the responses was also reported using lenalido-
mide as consolidation after FR or FCR treatment [41, 42].
Currently, lenalidomide is under evaluation for maintenance
“Continuum Studio” and in patients with monoclonal B
lymphocytosis.
Table 2 shows the different studies using lenalidomide in
combination with other agents in CLL patients.
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Table 2: Trials using lenalidomide in combination in CLL patients.
References Regimen No. TLS % TFR % AE 3-4 (%) Response
Chanan Khan
[31]
2006-7
Phase II
Relapsed or
refractory
Lenalidomide 10mg per day escalated up
to 5mg each 1-2 week (max 25mg) 21
days each 28
Rituximab 375mg/m2 days 1, 8, and 15
(cycle 1) and days 1 and 15 (cycles 2–6)
30 5 8
Neutropenia 70%
Thrombocytopenia 45%
Anemia 18%
ORR 57.7%
RC 18%
TFS 19.4 months
ORR 38% (high
risk cytogenetic)
James 2011 [30]
Phase II frontline
CLL Research
Consortium
CRC-014
Lenalidomide cycle 1: 2.5mg; cycles 2–7:
5mg escalated up to 10mg (days 1–21
each 28)
Rituximab: 50mg/m2 day 29; 325mg/m2
day 31; 375mg/m2 day 33 (cycle 1),
375mg/m2 weekly (cycle 2) and
375mg/m2 day 1 (cycles 3–7)
69 1.4
Neutropenia 49%
Thrombocytopenia 6%
Anemia 11%
ORR 95%
(<65 y)
ORR 78%
(>65 y)
RC 20% (<65 y)
RC 8% (>65 y)
TFS 19-20m
Badoux [29, 43]
Phase II relapsed
or refractory
Lenalidomide was started on day 9 at
cycle 1 and on day 1 of the cycles 3–12:
10mg continuously
Rituximab 375mg/m2 weekly during
cycle 1 and on day 1 cycles 3 to 12
59 1.7 27
Neutropenia 73%
Thrombocytopenia 34%
Anemia 15%
Infection 15%
ORR 66%
RC 12%
OS: 71% at 36
months
TFS: 17.4m
Veliz 2009 [32]
Phase II
Relapsed or
progression
after rituximab
Heavily treated
Lenalidomide cycle 1: 2.5mg (days 1–7),
5mg (days 8–15), 10mg (15–21 days)
followed by 7 days of rest and then 20mg
21 each 28 days
Rituximab 375mg/m2 weakly each 4
weeks (day 15)
10 (RF)12 12 Neutropenia 41%
ORR 30%
RC 0
Chen 2012 [39]
Phase II
frontline
Lenalidomide: 5mg per day escalated
5mg each 28 days (max 25mg)
Dexamethasone: 12mg days 1–4; 14, 21,
and 28
Maximum 18 cycles
18 0 5
Neutropenia 53%
Neutropenia febrile 24%
Thrombocytopenia 12%
0R 59%
RC 1%
RP 53%
Badoux [33]
Phase II
Relapsed or
refractory
Lenalidomide 10mg per day
Ofatumumab weekly 16 NR 13
Neutropenia 50%
Anemia 13%
ORR 63%
RC: 13%
OS: NR
TFS: NR
Ferrajoli [44]
2012
Phase II
Relapsed or
refractory
Lenalidomide 10mg day 9 continued for
24 months
Ofatumumab weekly for 3 weeks (300mg
week; 1000mg week 2 and thereafter)
monthly (months 2–6); every other
month (months 7–24)
36 0 0
Neutropenia 47%
Thrombocytopenia 9%
Anemia 6%
ORR 68%
RC 24%
Blum [38]
2011
Phase I
Relapsed or
refractory very
adverse
Lenalidomide 2.5mg escalating up to
25mg days 1–21
Flavopiridol 30mg/m2 in bolus followed
of 30–50 mg/m2 days 1, 8, and 15 (cycle 1)
and then days 3, 10 and 17
30 3 7
Neutropenia 47%
Thrombocytopenia 60%
Anemia 33%
ORR 57%
RC: 0%
OS 7m
TFS 23m
GIMEMA [34]
LLC 606
Phase I
Relapsed or
refractory
Lenalidomide 2.5mg escalating up to
15mg Cyclophosphamide Fludarabine 9 0 11
Neutropenia transitory
3-4 in the majority of the
patients
ORR 67%
RC 33%
NR
NR
Egle [36]
2011
Phase I/II
Frontline
Lenalidomide 2.5mg/day (days 7–21)
escalating up to 25mg (day 1–21)
Fludarabine 40mg/m2 1–3
Rituximab 375m/m2 day 3 cycle 1;
500mg/m2 day 1 cycles 2–6
Maintenance:
R: 375mg/m2 cycles 2, 4, and 6
Lenalidomide (maximum tolerated dose)
45 0 0 Neutropenia 88%
ORR 87%
RC 49%
NR
NR
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Table 2: Continued.
References Regimen No. TLS % TFR % AE 3-4 (%) Response
Flinn [45]
2012
Phase I-II
Frontline
Rituximab 375mg/m2 (cycle 1);
500mg/m2 (cycle 2–6)
Fludarabine 25mg/m2 (days 1–3)
Lenalidomide 2.5–5mg (days 8–28)
6 cycles
51 6 0
Neutropenia 47%
Anemia 14%
Thrombocytopenia 6
Rash 14%
ORR: 78%
RC 19%
PFS 71%
OS 88%
(median FU 21
months)
Brown [35]
Phase I
Frontline
Fludarabine: 25mg/m2 (days 3–5)
Rituximab: 50mg/m2 day 1 and
325mg/m2 day 3
Lenalidomide: 2.5mg to alternate days (21
each 28 days)
Followed by two cycles of consolidation
with lenalidomide
9 1/9 2/9
Neutropenia 66%
Thrombocytopenia 2/9
Allergy
Syndrome hand-foot
ORR 56%
RC 1/9
TLS: tumor lysis syndrome; TFR: tumor flare reaction; AE: adverse effects; NR: not reported; ORR: overall response; CR: complete remission; OS: overall
survival; TFS: treatment-free survival; y: year; m: month; RF: renal failure.
4. Dose and Schedule of Lenalidomide in
Patients with CLL
The 25mg dose used in early studies was associated with
excessive toxicity, and then subsequent trials started with
lower doses (2.5–5mg) progressively increased to 10–25mg.
In the majority of studies, the median of the tolerated
dose was 10mg. The use of lower doses may be associated
with lower response rates, and dose escalations must be
implemented to improve efficacy. Currently, daily doses used
in trials range between 2.5 and 10mg.
One of the open issues that needs further investiga-
tion is why a continuous dosing is more effective than 21
days schedules with a week off. The “recovery” of periph-
eral lymphocytosis observed using intermittent dosing of
lenalidomide led to the current continuous daily dosing [9],
since lymphocytosis recovery has not been noted in this
regimen. Continuous dosing may prevent the leukemia cells
recovery, inhibit the production of cytokines that promote
the leukemia cells survival, and may also prevent the support
of malignant cells by stromal cells [7]. Likewise, in patients
with adverse prognostic features who were heavily pretreated
and received 21 days of treatment with other 21 days off, the
decrease of the toxicity, but also the efficacy, was observed
[10].
As of yet, none of the clinical characteristics analyzed
have allowed us to predict the response to lenalidomide
treatment. Only one study reported that responders had a
higher number of neutrophils than nonresponders [9].
5. Side Effects
The most common grade 3-4 adverse events of lenalidomide
treatment were neutropenia, thrombocytopenia, and anemia.
Tumor lysis syndrome (TLS), tumor flare reaction (TFR), and
venous thromboembolism (VTE) will be discussed later. Skin
rash, elevated liver enzymes, and phosphorus (P) and calcium
(Ca) alterations are even more uncommon.
5.1. Tumor Flare Reaction (TFR). “Tumor flare reaction”
(TFR) is a side effect unique of lenalidomide treatment in
this disease that consists of the appearance of an increase in
swelling of lymph nodes, spleen, and liver, with or without
fever, erythema usually associated with local or generalized
rash (maculopapular, erythematous, and nonpruritic), bone
pain, and an increase in the number of lymphocytes. It is
a self-limited and transient effect and can be managed with
NSAIDs (ibuprofen 400–600mg/6 h) or a short course of
steroids in severe cases. It is important to recognize it to
avoid confusion with disease progression and improperly
discontinue the treatment.
Using a starting dose of 25mg, lenalidomide induced a
significant response in CLL patients, associated with tumor
lysis syndrome and TFR in a high percentage of cases [21].
These toxicities have been associated with a high starting
dose and a rapid escalation of lenalidomide. With high doses
of lenalidomide, it occurs within 6 days of treatment [7]; it
is more common in the first few cycles of therapy and in
previously untreated patients with a more robust immune
system [9]. Although TFR is most common during the first
cycle, repeated flare symptoms were also noted in 16% of the
cycles upon resuming the lenalidomide treatment after the
week off of each cycle, and it was observed as late as in cycle 28
[25]. It is alsomore common in patients with advanced stages
of the disease and in patients with lymph nodes larger than
5 cm [7]. Contrarily, it has not been described in cases with
low tumormass, where lenalidomide is used as consolidation.
TFR was significantly reduced using low starting doses
and using slower dose escalations [7]. In the study reported
by Chanan Khan, using 20mg of prednisone in the first 5
days and 10mg another 5 days as prophylaxis, there was a
decreasing in severity, but not in TFR incidence; nevertheless,
none of the patients had to stop the treatment or reduce the
dose. In this study, the onset of the syndromewas unrelated to
the previous lymphocyte count or burden of the disease [21].
In a clinical trial reported by Chen et al., almost one-third
of patients were treated with lower doses of prednisone (25–
50mg for 5–10 days) and TFR was common, but mild [9].
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The frequency of TFR also appears to be lower when
lenalidomide is used in combination with rituximab. Using
these drugs, TFRwas alsomilder (grades 1 and 2) and occured
during the first cycle of treatment [30]. The use of corticos-
teroids with lenalidomide plus dexamethasone is very inter-
esting since it has significant activity in previously untreated
CLL, is generally well tolerated and reduces dramatically
the incidence of TFR symptoms. However, the use of other
drugs with lenalidomide requires careful consideration of
dosing and scheduling; for example, sequential treatment
with ofatumumab and lenalidomide may be associated with
a higher rate of TFR (57%) than shown with concomitant
therapy [46].
It has been suggested that TFR, a side effect observed only
in CLL, may be secondary to the immune system activation.
Accordingly, it has been reported that it is highly correlated
with an overexpression of costimulatory molecules CD40,
CD80, and CD86; and consequently, this “flare” may be due
to an increased ability of leukemic B cells to present antigens
and inducing an antitumoral response [47]. Accordingly, TFR
has been correlated with clinical response [48]; however, this
association has not been corroborated in all studies. On the
other hand, it has also shown that progression-free survival
in TFR patients is not better [23, 49].
The development of TFR has also been reported as a pre-
dictor of response [50]; however, it has not been corroborated
in all studies.
5.2. Tumor Lysis Syndrome (TLS). Tumor lysis syndrome
(TLS) is a specific adverse event more common in patients
with high tumor burden or with regimens with a high
starting dose of lenalidomide. TLS is a group of metabolic
complications that appears after the lenalidomide treatment
caused by the release of breakdown products by the lysis
of leucemic cells. This syndrome includes hyperkalemia,
hyperphosphatemia, hyperuricemia, hyperuricosuria, and
hypocalcemia. It is mainly observed in the first 15 days of
the treatment and it is more common in patients with bulky
disease, moderate renal impairment, and elevated baseline
uric acid levels. In some cases, it may progress to renal failure
or arrhythmias that can be fatal [51].
Allopurinol (300mg) is used for the prophylaxis of TLS,
starting 3 days before the starting of the treatment and it is
also used at the first cycle of each dose escalation (Celgene
Corporation 2010). The dose should be adjusted in patients
with renal insufficiency and patients should be adequately
hydrated, drinking 8–10 glasses of water (240mL each glass)
a day for 14 days in the first cycle and for 14 days after each
dose escalation (always taking into account the patient’s car-
diovascular status and the possibility of overloading volume).
Additionally, uric acid, P, Ca, and creatinine levels must be
monitored; and patients with previous renal failure requiring
dialysis or having creatinine clearance lower than 60mL/min
should be excluded.
5.3. Venous Thromboembolism (VTE). Venous thromboem-
bolism occurs in 5% of patients at 2–4 months after the
starting lenalidomide treatment and can be avoided with
appropriate prophylaxis. It has been suggested that lenalido-
mide may increase the risk of VTE due to endothelial
cell damage caused by the presence of high TNF-𝛼 serum
levels; aspirin may be useful in its prophylaxis [50]. Celgene
has updated the prophylactic anticoagulation protocols in
patients with CLL; these guidelines include the use of aspirin
in patients with 0-1 risk factors for VTE and low molecular
weight heparin (40mg of enoxaparin or equivalent) or oral
anticoagulants (INR target of 2-3) in patients with 2 or more
thrombosis risk factors.
6. Conclusions
Lenalidomide alone or in combination (mainly with rit-
uximab) offered an effective therapeutic alternative for
patientswho relapsed after fludarabine-containing chemoim-
munotherapy. Consequently, it is necessary to prospectively
compare this combinationwith other commonly used salvage
regimens.We should pay special attention to TFR and TLS in
early cycles of treatment and it is important to recognize them
to avoid confusion with disease progression and improp-
erly suspend the treatment. Although clinical responses to
therapy occurred early in this treatment regimen, patients
who received a long-term therapy obtained an improvement
in the quality of the response. Durable responses may be
achieved, although it needs a long time and the treatment
must be prolonged until progression and/or CR. Shorter
treatments can be effective when lenalidomide is used in
combination with other drugs. Combination with agents
that act synergistically favouring the activity of the immune
system and agents which do not produce myelosuppression
is of particular interest.
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